Page 24 - Scientific Session News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Study raises more concerns about the use of combined EPA/DHA through supplements Doctors often recommend Omega-3s to help patients lower their cholesterol and improve heart health. Those Omega-3s can come from fatty fish like salmon and mackerel, or supplements that often contain a combination of the acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Now, a new study from the Intermountain Healthcare Heart Institute in Salt Lake City finds that higher EPA blood levels alone lowered the risk of major cardiac events and death in patients, while DHA blunted the cardiovascular bene...

 E-Mail IMAGE: New research from the Intermountain Healthcare Heart Institute in Salt Lake City finds that higher EPA blood levels alone lowered the risk of major cardiac events and death in patients,... view more  Credit: Intermountain Healthcare Doctors often recommend Omega-3s to help patients lower their cholesterol and improve heart health. Those Omega-3s can come from fatty fish like salmon and mackerel, or supplements that often contain a combination of the acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Now, new research from the Intermountain Healthcare He...

Doctors often recommend Omega-3s to help patients lower their cholesterol and improve heart health. Those Omega-3s can come from fatty fish like salmon

Executive Staff Leadership As the College’s more than 500 employees work to support the ACC Mission to transform cardiovascular care and improve heart health, they are led by an executive staff leadership team. Learn more about ACC’s staff leaders: Cathleen C. Gates, CEO Cathleen C. Gates serves as CEO of the American College of Cardiology. During her nearly 30-year tenure at the ACC, Gates has served in a variety of roles, including interim CEO, chief operating officer, chief financial officer and chief people officer. As CEO, Gates works closely with ACC's leaders and more than 500 sta...

(Provided Photo/Eli Lilly & Co.) by: Alex Brown, Inside INdiana Business Posted: Mar 1, 2021 / 11:59 AM EST INDIANAPOLIS (Inside INdiana Business) — Indianapolis-based Eli Lilly and Co. is reporting positive results from two Phase 3 clinical trials of a drug designed to help people with type 2 diabetes. Lilly says tirzepatide led to “significant A1C and body weight reductions” in adults with the disease during the trials.  Lilly Diabetes President Mike Mason says the treatment continued to achieve “consistent efficacy and safety results” in adults with type 2 diabetes, regardless ...